{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:43Z","timestamp":1786975603063,"version":"build-2736575974"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamadermatol.2018.2352","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T11:31:17Z","timestamp":1533727877000},"page":"1152","source":"Crossref","is-referenced-by-count":152,"title":["Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes"],"prefix":"10.1001","volume":"154","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Bergman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi180036r1","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study.","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"8","key":"doi180036r2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France.","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi180036r3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions.","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"issue":"8","key":"doi180036r4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archderm.131.8.957","article-title":"Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany.","volume":"131","author":"Zillikens","year":"1995","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi180036r5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ijd.2018.57.issue-1","article-title":"Ethnic variations in the epidemiology of bullous pemphigoid in Israel.","volume":"57","author":"Kridin","year":"2018","journal-title":"Int J Dermatol"},{"issue":"2","key":"doi180036r6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/15569527.2016.1211670","article-title":"A case of bullous pemphigoid induced by vildagliptin.","volume":"36","author":"Keseroglu","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"issue":"2","key":"doi180036r7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous pemphigoid associated with linagliptin treatment.","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi180036r8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors\u2013one due to linagliptin.","volume":"232","author":"Mendon\u00e7a","year":"2016","journal-title":"Dermatology"},{"issue":"2","key":"doi180036r9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jdv.2012.26.issue-2","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi180036r10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/fcp.2015.29.issue-1","article-title":"Bullous pemphigoid induced by vildagliptin: a report of three cases.","volume":"29","author":"B\u00e9n\u00e9","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"doi180036r11","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases.","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"doi180036r12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","article-title":"A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.","volume":"149","author":"Aouidad","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi180036r13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors: a case report and review of literature.","volume":"8","author":"Attaway","year":"2014","journal-title":"J Dermatol Case Rep"},{"issue":"2","key":"doi180036r14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi180036r15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"doi180036r16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland.","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"doi180036r17","first-page":"S0022-202X(18)30110-6","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study.","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi180036r18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi180036r19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States.","volume":"59","author":"Parker","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi180036r20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaad.2014.05.006","article-title":"Mortality of patients with bullous pemphigoid\u00a0in Korea.","volume":"71","author":"Lee","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi180036r21","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis.","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi180036r22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1067\/mjd.2002.120445","article-title":"Subacute prurigo variant of bullous pemphigoid: autoantibodies show the same specificity compared with classic bullous pemphigoid.","volume":"47","author":"Schmidt","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi180036r23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/ijd.2006.45.issue-3","article-title":"Prodromal bullous pemphigoid.","volume":"45","author":"Lamb","year":"2006","journal-title":"Int J Dermatol"},{"issue":"2 Pt 2","key":"doi180036r24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0190-9622(93)70179-W","article-title":"Nonbullous pemphigoid: prodrome of bullous pemphigoid or a distinct pemphigoid variant?","volume":"29","author":"Strohal","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi180036r25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/archderm.1979.04010030028010","article-title":"Localized pemphigoid simulating dyshidrosiform dermatitis.","volume":"115","author":"Levine","year":"1979","journal-title":"Arch Dermatol"},{"issue":"11","key":"doi180036r26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid.","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi180036r27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/jde.2018.45.issue-5","article-title":"Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J Dermatol"},{"key":"doi180036r28","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2741\/2785","article-title":"Dipeptidyl peptidase IV (DPP IV\/CD26) is a cell-surface plasminogen receptor.","volume":"13","author":"Gonzalez-Gronow","year":"2008","journal-title":"Front Biosci"},{"issue":"7","key":"doi180036r29","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/jid.2008.424","article-title":"Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97.","volume":"129","author":"Hofmann","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi180036r30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo.","volume":"181","author":"Forssmann","year":"2008","journal-title":"J Immunol"},{"key":"doi180036r31","doi-asserted-by":"publisher","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight.","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamadermatology\/fullarticle\/2695085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T16:11:01Z","timestamp":1539187861000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.2352"}},"subtitle":["Estimating the Risk of the New Agents and Characterizing the Patients"],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.2352","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}